Equities research analysts expect Teladoc Inc (NYSE:TDOC) to announce earnings per share (EPS) of ($0.42) for the current fiscal quarter, according to Zacks. Nine analysts have provided estimates for Teladoc’s earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.50). Teladoc posted earnings per share of ($0.31) during the same quarter last year, which indicates a negative year over year growth rate of 35.5%. The firm is scheduled to issue its next earnings results on Wednesday, March 7th.

According to Zacks, analysts expect that Teladoc will report full-year earnings of ($1.57) per share for the current financial year, with EPS estimates ranging from ($1.65) to ($1.52). For the next fiscal year, analysts expect that the firm will report earnings of ($1.23) per share, with EPS estimates ranging from ($1.67) to ($0.78). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow Teladoc.

Teladoc (NYSE:TDOC) last announced its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.25). The company had revenue of $68.70 million during the quarter, compared to analyst estimates of $67.53 million. Teladoc had a negative net margin of 39.61% and a negative return on equity of 21.59%. The firm’s revenue for the quarter was up 112.0% compared to the same quarter last year. During the same quarter last year, the business earned ($0.33) EPS.

A number of equities analysts have recently commented on TDOC shares. Oppenheimer raised their target price on shares of Teladoc from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Tuesday, November 21st. Zacks Investment Research downgraded shares of Teladoc from a “buy” rating to a “hold” rating in a research note on Wednesday, October 18th. Cantor Fitzgerald reissued a “hold” rating on shares of Teladoc in a research note on Monday, August 28th. BidaskClub downgraded shares of Teladoc from a “hold” rating to a “sell” rating in a research note on Wednesday, November 15th. Finally, Deutsche Bank assumed coverage on shares of Teladoc in a research note on Friday. They set a “buy” rating and a $39.00 price target on the stock. One research analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $39.15.

In other news, CEO Jason N. Gorevic sold 20,000 shares of the business’s stock in a transaction dated Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the completion of the sale, the chief executive officer now owns 838,261 shares of the company’s stock, valued at approximately $26,908,178.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Mark Hirschhorn sold 30,000 shares of the business’s stock in a transaction dated Monday, December 4th. The stock was sold at an average price of $32.99, for a total transaction of $989,700.00. Following the completion of the sale, the chief financial officer now directly owns 5,203 shares of the company’s stock, valued at approximately $171,646.97. The disclosure for this sale can be found here. Insiders sold a total of 265,000 shares of company stock valued at $8,697,400 in the last three months. Insiders own 4.47% of the company’s stock.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. ETF Managers Group LLC acquired a new position in shares of Teladoc in the 2nd quarter valued at about $104,000. Bank of Montreal Can boosted its holdings in shares of Teladoc by 214.2% in the 2nd quarter. Bank of Montreal Can now owns 3,516 shares of the health services provider’s stock valued at $123,000 after buying an additional 2,397 shares during the period. Pacad Investment Ltd. acquired a new position in shares of Teladoc in the 2nd quarter valued at about $135,000. Fred Alger Management Inc. acquired a new position in shares of Teladoc in the 2nd quarter valued at about $139,000. Finally, Ameritas Investment Partners Inc. boosted its holdings in shares of Teladoc by 134.2% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,724 shares of the health services provider’s stock valued at $164,000 after buying an additional 2,707 shares during the period.

Teladoc (NYSE TDOC) opened at $32.30 on Tuesday. Teladoc has a one year low of $15.65 and a one year high of $37.90. The company has a current ratio of 5.08, a quick ratio of 5.08 and a debt-to-equity ratio of 0.83.

TRADEMARK VIOLATION NOTICE: This report was originally reported by American Banking News and is owned by of American Banking News. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://www.americanbankingnews.com/2017/12/12/zacks-analysts-expect-teladoc-inc-tdoc-will-announce-earnings-of-0-42-per-share.html.

Teladoc Company Profile

Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.

Get a free copy of the Zacks research report on Teladoc (TDOC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Teladoc Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Inc and related companies with MarketBeat.com's FREE daily email newsletter.